首页> 外文期刊>Arzneimittel-Forschung: =Drug Research >In vivo bioequivalence of oral antidiabetic agents: pioglitazone tablets.
【24h】

In vivo bioequivalence of oral antidiabetic agents: pioglitazone tablets.

机译:口服降糖药的体内生物等效性:吡格列酮片。

获取原文
获取原文并翻译 | 示例
           

摘要

The study was designed to evaluate the bioequivalence of two pioglitazone (CAS 112529-15-4) formulations. The trial was performed in 26 healthy male volunteers with the aim of comparing a new generic product (tablets containing 30 mg pioglit-azone hydrochloride, test) with the originator product (reference). The trial was performed according to an open, crossover design in one study centre. In each of the two study periods (separated by a wash-out of 14 days) a single oral dose of 30 mg (test or reference) formulation was administered. Blood samples were taken up to 120 h post dose, the plasma was separated and the concentrations of pioglitazone and its principal active metabolite hydroxypioglitazone were determined by LC-MS-MS method. AUC0-inf, AUC0-t, Cmax, and Tmax were calculated for both formulations. The mean Cmax of pioglitazone ranged between 1.01 microg/mL and 1.05 microg/mL, while the mean AUC0-inf and AUC0-t ranged between 10.89 microg x h/mL and 10.98 microg x h/mL as well as between 10.56 microg x h/mL and 10.62 microg x h/mL for the test and reference formulations, respectively. The median Tmax for the test tablets was 1.50 h and for the reference was 1.75 h. The ratios test/reference formulation for AUC0-inf, AUC0-t and Cmax were 99.70%, 100.13% and 99.17%, respectively. Furthermore, the 90% geometric confidence intervals of the mean ratio of In-transformed AUC0-inf were narrow and symmetrical around 100%, i.e. 90.59% to 109.72%, for AUC0-t, 90.69% to 110.55%, whereas for Cmax they were 87.52% to 112.37%. As in the case of pioglitazone, mean values of the principal bioequivalence parameters of hydroxypioglitazone did not differ significantly after administration of the test and reference formulations. In the light of the present study it can be concluded that the two evaluated pioglitazone formulations, i.e. test formulation of pioglitazone hydrochloride and reference formulation, are bioequivalent in terms of the rate and extent of absorption.
机译:该研究旨在评估两种吡格列酮(CAS 112529-15-4)制剂的生物等效性。该试验是在26位健康的男性志愿者中进行的,目的是将一种新的仿制产品(含有30 mg吡格列酮-氮杂酸盐的片剂,测试)与原始产品(参考)进行比较。该试验是根据一个研究中心的开放式交叉设计进行的。在两个研究阶段的每个阶段(以14天的冲洗时间分隔),均给予30 mg(测试或参考)制剂的单次口服剂量。给药后120小时采集血样,分离血浆,并通过LC-MS-MS方法测定吡格列酮及其主要活性代谢物羟基吡格列酮的浓度。两种配方均计算了AUC0-inf,AUC0-t,Cmax和Tmax。吡格列酮的平均Cmax在1.01微克/毫升和1.05微克/毫升之间,而平均AUC0-inf和AUC0-t的范围在10.89微克xh /毫升和10.98微克xh /毫升之间,以及10.56微克xh /毫升和测试配方和参考配方分别为10.62 microg xh / mL。测试片剂的中值Tmax为1.50 h,而参考值为1.75 h。 AUC0-inf,AUC0-t和Cmax的比率测试/参考配方分别为99.70%,100.13%和99.17%。此外,In转化的AUC0-inf平均比率的90%几何置信区间狭窄且对称,大约为100%,即AUC0-t为90.59%至109.72%,而Cmax为90.69%至110.55%。 87.52%至112.37%。与吡格列酮的情况一样,在施用测试和参考制剂后,羟基吡格列酮的主要生物等效性参数的平均值无显着差异。根据本研究,可以得出结论,两种评估的吡格列酮制剂,即吡格列酮盐酸盐的测试制剂和参考制剂,在吸收速率和程度方面是生物等效的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号